Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Notes Payables (2021 - 2023)

Avalo Therapeutics' Notes Payables history spans 3 years, with the latest figure at $14.1 million for Q2 2023.

  • For Q2 2023, Notes Payables changed N/A year-over-year to $14.1 million; the TTM value through Jun 2023 reached $14.1 million, changed N/A, while the annual FY2022 figure was $5.9 million, N/A changed from the prior year.
  • Notes Payables reached $14.1 million in Q2 2023 per AVTX's latest filing, up from $9.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $33.2 million in Q1 2022 to a low of $2.6 million in Q3 2022.
  • Average Notes Payables over 3 years is $16.4 million, with a median of $14.1 million recorded in 2023.
  • Peak YoY movement for Notes Payables: plummeted 92.11% in 2022, then tumbled 71.99% in 2023.
  • A 3-year view of Notes Payables shows it stood at $32.5 million in 2021, then crashed by 81.74% to $5.9 million in 2022, then soared by 138.03% to $14.1 million in 2023.
  • Per Business Quant, the three most recent readings for AVTX's Notes Payables are $14.1 million (Q2 2023), $9.3 million (Q1 2023), and $5.9 million (Q4 2022).